Telix Pharmaceuticals (NASDAQ:TLX) Stock Price Down 4.5% – Time to Sell?

Telix Pharmaceuticals Limited (NASDAQ:TLX) shares fell 4.5% during mid-day trading on Wednesday . The stock traded as low as $11.15 and last traded at $11.1650. 16,654 shares traded hands during trading, a decline of 92% from the average daily volume of 196,120 shares. The stock had previously closed at $11.69.

Analysts Set New Price Targets

TLX has been the subject of a number of research reports. Royal Bank Of Canada downgraded Telix Pharmaceuticals from an “outperform” rating to a “sector perform” rating in a research report on Friday, July 17th. Citigroup restated a “buy” rating on shares of Telix Pharmaceuticals in a research note on Thursday, August 20th. Weiss Ratings raised Telix Pharmaceuticals from a “sell (d)” rating to a “hold (c-)” rating in a research report on Friday, August 21st. HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of Telix Pharmaceuticals in a research note on Tuesday, July 7th. Finally, Wedbush reiterated an “outperform” rating and set a $22.00 price target on shares of Telix Pharmaceuticals in a research note on Thursday, August 20th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $20.40.

Telix Pharmaceuticals Stock Performance

The company’s fifty day moving average price is $11.10 and its two-hundred day moving average price is $9.79. The company has a quick ratio of 1.85, a current ratio of 2.01 and a debt-to-equity ratio of 1.16.

Hedge Funds Weigh In On Telix Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in TLX. Russell Investments Group Ltd. acquired a new stake in shares of Telix Pharmaceuticals during the second quarter worth approximately $975,000. Jane Street Group LLC acquired a new position in shares of Telix Pharmaceuticals in the 2nd quarter worth approximately $564,000. IHT Wealth Management LLC acquired a new position in shares of Telix Pharmaceuticals in the 2nd quarter worth approximately $213,000. Rhumbline Advisers grew its position in Telix Pharmaceuticals by 117.3% during the 3rd quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock worth $25,000 after acquiring an additional 1,392 shares during the last quarter. Finally, JPMorgan Chase & Co. bought a new stake in Telix Pharmaceuticals during the 3rd quarter worth approximately $243,000.

About Telix Pharmaceuticals

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.